VOYA Investment Management
NKTR icon

VOYA Investment Management’s Nektar Therapeutics NKTR Stock Holding History

VOYA Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,785
Closed -$181K – 2713
2025
Q1 		$181K Buy
17,785
+5,673
+47% +$74.1K ﹤0.01% 2309
2024
Q4 		$169K Buy
12,112
+8,079
+200% +$142K ﹤0.01% 2441
2024
Q3 		$78.6K Sell
4,033
-97
-2% -$1.85K ﹤0.01% 2707
2024
Q2 		$76.8K Buy
+4,130
New +$87K ﹤0.01% 2732
2023
Q2 		– Sell
-16,762
Closed -$177K – 2973
2023
Q1 		$177K Sell
16,762
-35
-0.2% -$1.06K ﹤0.01% 2573
2022
Q4 		$569K Buy
16,797
+2,987
+22% +$145K ﹤0.01% 1960
2022
Q3 		$663K Buy
13,810
+4,017
+41% +$239K ﹤0.01% 1846
2022
Q2 		$558K Buy
9,793
+5,957
+155% +$376K ﹤0.01% 1763
2022
Q1 		$310K Buy
3,836
+394
+11% +$58.3K ﹤0.01% 2158
2021
Q4 		$697K Buy
3,442
+1,534
+80% +$333K ﹤0.01% 1792
2021
Q3 		$514K Buy
1,908
+22
+1% +$5.29K ﹤0.01% 2032
2021
Q2 		$486K Sell
1,886
-3,230
-63% -$894K ﹤0.01% 2108
2021
Q1 		$1.53M Buy
5,116
+3,405
+199% +$1.06M ﹤0.01% 1318
2020
Q4 		$436K Sell
1,711
-108
-6% -$27.9K ﹤0.01% 2001
2020
Q3 		$453K Sell
1,819
-58
-3% -$18.2K ﹤0.01% 1729
2020
Q2 		$652K Sell
1,877
-428
-19% -$134K ﹤0.01% 1486
2020
Q1 		$617K Buy
2,305
+8
+0.3% +$2.47K ﹤0.01% 1495
2019
Q4 		$744K Sell
2,297
-3,120
-58% -$905K ﹤0.01% 1638
2019
Q3 		$1.48M Sell
5,417
-31
-0.6% -$11.4K ﹤0.01% 1138
2019
Q2 		$2.91M Sell
5,448
-505
-8% -$253K 0.01% 944
2019
Q1 		$3M Sell
5,953
-122
-2% -$72.3K 0.01% 937
2018
Q4 		$3M Buy
6,075
+21
+0.3% +$12.7K 0.01% 899
2018
Q3 		$5.54M Sell
6,054
-108
-2% -$92.2K 0.01% 797
2018
Q2 		$4.51M Sell
6,162
-41,543
-87% -$47.9M 0.01% 850
2018
Q1 		$76M Sell
47,705
-7,600
-14% -$9.79M 0.16% 144
2017
Q4 		$49.5M Buy
55,305
+50,711
+1,104% +$30M 0.1% 208
2017
Q3 		$1.65M Hold
4,594
– – ﹤0.01% 1136
2017
Q2 		$1.35M Buy
4,594
+769
+20% +$222K ﹤0.01% 1218
2017
Q1 		$1.35M Hold
3,825
– – ﹤0.01% 1186
2016
Q4 		$704K Hold
3,825
– – ﹤0.01% 1550
2016
Q3 		$986 Sell
3,825
-2,368
-38% -$610K ﹤0.01% 1327
2016
Q2 		$1.32M Hold
6,193
– – ﹤0.01% 1145
2016
Q1 		$1.28M Buy
6,193
+2,270
+58% +$436K ﹤0.01% 1161
2015
Q4 		$992K Sell
3,923
-68,047
-95% -$14M ﹤0.01% 1290
2015
Q3 		$11.8M Sell
71,970
-35,092
-33% -$6.21M 0.03% 503
2015
Q2 		$20.1M Buy
107,062
+22,462
+27% +$3.87M 0.05% 347
2015
Q1 		$14M Buy
84,600
+17,176
+25% +$3.53M 0.03% 468
2014
Q4 		$15.7M Sell
67,424
-11,353
-14% -$2.43M 0.03% 440
2014
Q3 		$14.3M Buy
78,777
+15,153
+24% +$2.9M 0.03% 461
2014
Q2 		$12.2M Sell
63,624
-5,720
-8% -$1.01M 0.03% 527
2014
Q1 		$12.6M Sell
69,344
-5,973
-8% -$1.18M 0.03% 500
2013
Q4 		$12.8M Buy
75,317
+16,933
+29% +$2.73M 0.03% 498
2013
Q3 		$9.15M Buy
58,384
+9,447
+19% +$1.75M 0.02% 586
2013
Q2 		$8.48M Buy
+48,937
New +$7.51M 0.02% 606

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VOYA Investment Management's NKTR Position: Q2 2025 in Review

VOYA Investment Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 17,785 shares — an estimated $181K sold.

VOYA Investment Management first reported a position in NKTR in Q2 2013 and held it in 44 quarters. The position peaked at $76M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • VOYA Investment Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • VOYA Investment Management sold 17,785 Nektar Therapeutics shares in Q2 2025, an estimated $181K.
  • VOYA Investment Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 44 quarters.
  • VOYA Investment Management's Nektar Therapeutics position peaked at $76M in Q1 2018.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on VOYA Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.